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Abstract
Biobanks require new governance models that address their ethical and regulatory challenges. One
model relies on stewardship of specimens throughout their life course. Here, we discuss findings
from our survey of 456 U.S. biobank managers that addressed whether and how biobanks steward
their specimens. The findings reveal that most bio-banks do not create ongoing relationships with
contributors but do practice stewardship over storing and sharing of specimens. Biobanks now
need guidance to fully articulate stewardship practices that ensure respect for contributors while
facilitating research.
The use of biobanks to collect and store human specimens for biomedical research has
raised questions about protections for specimen contributors. The regulatory framework for
informed consent for research requires an explicit description of the reasons for specimen
and data collection, the potential risks and benef ts associated with their use, the specif
cation of future users and uses, and a stated duration of research activity (1). These
expectations are bending under the weight of a paradigm shif brought about by researchers
who turn to biobanks, rather than to individuals, to obtain specimens (2, 3). Biobanks often
collect specimens for unspecified, unpredictable uses, and their relationships with specimen
contributors are increasingly hard to define because biobanks acquire specimens both
directly and from other collectors. Many consent forms now incorporate agreement to broad,
unrestricted use with no specified end date, a trend encouraged by funding agencies,
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specimens and data (4, 5). At the same time, the rise of large-scale genomic technology and
new f ndings about the inherent identif ability of specimens have introduced challenging
questions about responsibilities researchers or institutions have to those who contribute
human specimens (6). Professional societies have begun to address these responsibilities, but
guidance is far from settled (7–9).
Emerging models of biobank governance, such as stewardship, attempt to address these
complexities (10, 11). In proposing that biobanks are stewards of the resources they
maintain, the stewardship model identifies biobanks’ obligations to contributors throughout
the “life” of the specimen, even as the strength and duration of their relationships with the
original contributors change (10). The stewardship role may extend to identified
communities when the sources of specimens are linked by geography, disease condition, or
another feature. Biobanks might offer forms of community engagement—such as those
designed to enhance understanding of the research or improve experimental design; invite
joint governance (12, 13); or return individual-level or aggregate research results to
contributors (3, 14, 15). The stewardship model also requires biobanks, in their relationships
with researchers, to ensure that specimens and data are used for agreed-upon purposes set
forth in the terms of consent or the biobank mission (11). These governance practices thus
define broader responsibilities and more complex research relationships for biobanks than
have been typical in the past.
Another key attribute of the stewardship model is proper internal care and oversight of the
stored specimens. Oversight agencies and professional societies promote their own best
practice standards (16, 17) that also include adherence to federal regulatory protections for
contributors and data-sharing policies when applicable. These standards do not invoke
stewardship terminology, but they are consonant with features of the model.
Although the stewardship model is viewed favorably as a frame for addressing ethical issues
raised by the complexities of research that relies on banked specimens, there is a dearth of
empirical information on how stewardship is implemented in practice. Data from our 2012
survey provide the opportunity to examine three sets of biobank practices relevant to this
model: practices related to contributors, practices within the biobank, and practices related
to researchers.
PRACTICES CONCERNING CONTRIBUTORS
We examined biobank practices that address whether and how contributors are informed that
their specimens will be stored, and whether contributors are financially compensated for
their specimens, given individual or aggregate results, or sent a newsletter.
Informing donors about storage and use
To determine whether and how contributors are informed that their specimens will be stored
for future research, biobank managers were first asked whether specimen contributors are
typically informed that their specimens will be stored (Fig. 1A); 96% responded “yes”; 3%
responded that contributors are not typically informed; 2% were “not sure.” The 412
respondents who said “yes” or “not sure” were then asked whether the biobank ever accepts
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specimens from contributors who are not informed that their specimens will be stored, and
10% (41 respondents) said “yes.” We did not ask whether the biobank itself informed
contributors about storage, because contributors may be informed by an individual or
organization not related to the biobank, such as a researcher or a hospital that collected the
biological specimens.
Of the 404 biobank respondents who said that contributors are typically informed about
storage of their specimens, 79% reported that the approach typically used is an opt-in
method [defined as “contributors (or their surrogates) are asked for permission to store their
specimens”]; 12% reported that it is typically an opt-out method [“contributors (or their
surrogates) are notified that their specimens will be stored unless they refuse”]; and 9%
reported that it is typically some “other” method. Among the 314 biobanks typically using
an opt-in method, 76% report use of global or broad consent for future research uses, 16%
report a limited consent for certain kinds of research uses, 5% report uses of both types, and
2% wrote in a response that was later coded as a “tiered” approach, meaning that
contributors are given an option in the consent form to allow their specimens to be used for
broad or limited purposes. Of the 35 biobank respondents who reported that they used
“other” methods, 13 wrote that they use both opt-in and opt-out consents, while the
remaining 22 declined to answer or described other situations that could not be classified as
either opt-in or opt-out.
Return of results and f nancial com-pensation
We also asked whether a bio-bank had access to identifying information for any of its
specimen contributors—information that would be needed in order to return results directly
to contributors; 72% responded “yes,” 23% “no.” (Fig. 1B). For the 327 biobanks in our
survey with access to identifying information, we asked whether the biobank ever offers
specimen contributors individual results from research that uses their specimens; 19% said
“yes,” 81% said “no.” When asked if the biobank ever offers aggregate research results to
contributors 38% said “yes,” 62% said “no.” Cross-tabulation shows that biobanks that offer
individual results are also more likely to offer aggregate results to contributors. Of those that
offer individual results, 56% also offer aggregate results; of those that do not offer
individual results, only 33% offer aggregate results (56 versus 33%; chi-square, P < 0.01).
When asked whether the biobank ever provides f nancial compensation to specimen
contributors, 18% indicated that they do, while 82% do not.
We hypothesized that returning results (either individual or aggregate) directly to
contributors might be viewed by a biobank as a form of compensation, and thus less
common if a biobank provides f nancial compensation to contributors. However, we found
no relationship between “ever offering f nancial compensation” and “ever returning
individual results.” In contrast, we found a positive association between “ever providing
financial compensation” and “ever providing aggregate results” (64 versus 37%; chi-square,
P < 0.01). Among the bio-banks that ever pay contributors, 64% offer aggregate results,
while among those that do not pay, only 37% offer aggregate results.
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When asked whether the biobank had sent a newsletter to specimen contributors in the past
two years, 20% reported that they had done so. Among biobanks that have sent a newsletter
within the past two years, 28% offer individual research results; of those that have not sent
newsletters, only 14% do so (28 versus 14%; chi-square, P < 0.05). Biobanks that have sent
newsletters are also more likely to offer aggregate research results than those that have not
(78 versus 28%; chi-square P < 0.001).
Sets of contributor practices
Important elements of a biobank's relationship with its contributors can be drawn from both
bioethics literature and human subjects regulations. In order to explore relationships that
might be obscured by looking at each contributor practice independently, we explored four
of the practices described above in combination: providing financial compensation, sending
a newsletter, and returning individual and aggregate results. In this way, we could
distinguish biobanks that take a minimalist approach, engaging in few or none of these
practices, from others that take a maximalist approach by using most or all of these
practices. Likewise, biobanks might regard these practices as substitutes for one another—
for example, giving aggregate results or individual results, but not both.
Our analysis was, by necessity, limited to those biobanks that could maintain direct
relationships with contributors. Thus, we excluded biobanks that do not keep identifying
information, that only collect specimens from secondary sources (not from individuals
directly), and that store only postmortem specimens. After excluding these, 224 biobanks
remained. Thus, the first result of our analysis is that only about half (51%) of our surveyed
biobanks are in a position to create and sustain a relationship with contributors over time.
We analyzed all possible combinations of the four contributor practices among the 224
biobanks (table S1). The largest number of these biobanks, 100 (45%), reported using none
of the four contributor practices (row 16). Fifty-five biobanks (25%) reported using only one
of the four practices (rows 8, 12, 14, and 15); of these, the most common approach was to
give aggregate results only (n = 32, row 14). Forty-five biobanks (20%) reported using two
practices (rows 4, 6, 7, 10, 11, and 13); and 19 (8%) reported using 3 practices (rows 2, 5,
and 9). Only five bio-banks (2%) report using all four contributor practices (row 1).
Of biobanks that ever pay contributors, 77% also engage in at least one other relationship-
building practice. Among bio-banks that do not ever pay, 47% also provide at least one other
service (77 versus 47%; chi-square, P < 0.01). Thus, as we found in our bivariate analyses, if
a biobank ever pays contributors, it is more, not less, likely to ever provide individual or
aggregate results or have sent a newsletter in the past two years.
PRACTICES WITHIN THE BIOBANK
Practices that entail stewardship of the specimens within the biobank are described in the
technical literature as best practices (18), but such stewardship is rarely discussed in the
bioethics literature. Although steward-ship within the biobank was not a main focus of our
survey, we have some measures that address it. Ninety-four percent of bio-bank respondents
reported that their bio-bank has standard operating procedures for processing specimens.
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Eighty-five percent reported having a computerized laboratory information management
system (LIMS), which we defined as a computer-based inventory system that tracks the
location and status of every specimen in the biobank. To provide oversight for proper
research uses of the stored specimens, 90% of biobanks require IRB approval from
researchers requesting specimen use; 26% have a community advisory board (not defined
for our respondents); and 81% reported having other oversight boards, such as a scientific
review committee or internal advisory board. Finally, we examined two practices that have
been recommended in the best practice literature (16, 17): a business plan and a plan for
specimens if the bank closes. Just 34% of biobanks have a formal business plan; 26% have a
written plan for specimens upon termination of the biobank (19).
PRACTICES CONCERNING RESEARCHERS
Next, we examined how the biobank's role as steward may be reflected in the practices that
guide interactions with researchers using its specimens. To begin, we asked respondents the
number of requests the biobank typically receives per year for specimens or associated data.
Most biobanks (70%) receive between 1 and 50 requests per year, distributed fairly evenly
across the categories of 1 to 5, 6 to 15, and 16 to 50 requests; the most common response
was 1 to 5 (27%). The remaining biobanks receive between 51 to 100 (12%), 101 to 500
(9%), 501 to 1000 (2%), and over 1000 requests (3%). The majority of respondents (77%)
indicated that researchers typically receive both specimens and data; 20% reported that they
typically receive specimens only, and 3% said researchers typically receive only data.
Procedures for acquiring specimens
We examined procedures for acquiring specimens in three ways: asking whether the biobank
(i) has application forms for specimen and/or data use; (ii) charges researchers for
specimens; and/or (iii) has standardized material transfer agreements (MTAs). Eighty-two
percent of biobanks have application forms; 41% typically charge researchers for specimens
(beyond just shipping or handling charges); and 78% have standardized MTAs. Table S2
shows the relationship between each of these three measures and the average reported
number of requests for specimens each year. For each measure, we found a monotonic trend:
The larger the number of requests, the more likely it was that biobanks have application
forms, (chi-square, P < 0.05), typically charge for specimens (chi-square, P < 0 0.01), and
have standardized MTAs (chi-square, P < 0.05). For application forms, values ranged from a
low of 61% to a high of 89%. The percent of biobanks that charge for specimens ranged
from 0 to 52%. Among the biobanks with the lowest number of requests per year, 67% had
MTAs, rising to 86% for biobanks receiving 16 to 50 requests per year, and then a slight
decrease to 82% among the banks with more than 50 requests per year. Finally, we explored
whether there is any relationship between financial practices for contributors and for
researchers, but found no relationship between ever offering financial compensation to
contributors and typically charging researchers for specimens.
Limiting researcher access
In response to themes raised in the bioethics literature about limited versus broad access, we
measured, in two ways, whether biobanks restrict researcher access to their specimens and
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data. First, we asked biobank respondents whether they approve all, some, or none of the
requests they receive. Forty-one percent approve all, 58% approve some, and 2 biobanks
(<1%) said they approve none. We followed up with an open-ended question that asked
under what circumstances requests for specimens or associated data are not approved (Table
1). Respondents offered one or several reasons, the most common of which were scientific
merit of the proposed research (57%) and lack of specimen availability (43%). The latter
includes statements that explicitly reference balancing availability against the merit of the
proposed use. Second, we asked whether biobanks give certain researchers priority access to
their specimens. Forty-six percent of biobank respondents reported that they do. We did not
define or ask respondents to define “priority access.” Instead, on the basis of responses to an
open-ended question in our pilot study, we provided a list of possible factors and asked
biobank respondents to indicate which ones were considered in determining a researcher's
priority level. The factors most frequently cited for determining priority access were
scientific merit of the proposed study (66%) and feasibility of the study (56%) (Table 2).
In addition to limiting who can use specimens or data from its collection, a biobank might
limit the nature of the specimens or data provided to researchers. Thus, we asked whether
biobanks ever provide identifying information about contributors to researchers who obtain
specimens or data. Among the 77% of biobanks with access to identifying information about
their contributors, only 18% (n = 56) report ever providing identifying information to
researchers who obtain their specimens or data. When asked in an open-ended question to
describe the circumstances under which identifiers are provided, 59% said when approved
by an IRB, 20% said when contributors consented to release, and 21% listed other reasons
specific to their situation.
Biobank reach-through
To explore biobanks’ role as stewards for the life of specimens, we asked about the degree
to which they maintain or relinquish control of what happens to the specimens or data after
they leave the biobank (so-called reach-through). A third (33%) of biobanks require
researchers to return remaining specimens to the biobank at the conclusion of the research
project; 21% require that remaining specimens be destroyed. The remaining bio-banks
(43%) place no requirements on disposition of the specimens (Fig. 2). Biobanks that require
researchers to pay for specimens (beyond shipping and handling costs) are less likely to
require that researchers return the specimens (26 versus 38%; chi-square, P < 0.05) or
destroy them (24 versus 40%; chi-square, P < 0.01). Another method of reach-through is not
linked to the physical specimens, but to the results generated. We found that 54% of
biobanks require the researcher using its specimens to share aggregate results of the research
with the bio-bank. Biobanks that require researchers to pay for specimens are less likely to
require researchers to share aggregate results with the biobank (45 versus 60%; chi-square,
P < 0.01). Thus, these bivariate analyses seem to show that when biobanks require
researchers to pay for specimens, they exert less reach-through control over specimens or
results generated.
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Sets of researcher practices
As with contributor practices, we examined researcher practices in combination in order to
identify patterns that might be obscured by viewing each practice independently. We
included measures that might be related to stewardship of the specimens as they are released
to and used by researchers: requiring payment for specimens; limiting researcher access by
denying certain requests or only letting researchers who contribute specimens to the biobank
use its specimens; requiring return or destruction of remaining specimens; and requiring
sharing of aggregate research results with the biobank. We did not include application forms
or standardized MTAs in the matrix because they are so commonly used among biobanks
(82 and 78%, respectively). Our analysis excludes the few biobanks that, on average, receive
zero requests per year for specimens and those that typically get requests for data only.
Table S3 presents a matrix of the remaining 370 biobanks as they fall into sets of researcher
practices. Only 6% (n = 24) of biobanks report no restrictions for researchers (row 16).
Thus, the majority of biobanks restrict researchers’ use of specimens, from as few as one
restriction to as many as all four of the practices we examined. The most common set of
practices, representing 17% (n = 64) of biobanks (row 9), is exhibited by biobanks that do
not require payment but do limit access, require return or destruction of specimens, and
require researchers to share aggregate results with the biobank. In fact, biobanks that do not
require payment are more likely to require all three restrictions than are those that do require
payment (30 versus 20%; chi-square, P < 0.05). The remaining 83% of biobanks are
distributed fairly equally across the other possible sets of practices. In contrast to the matrix
for contributor-oriented practices, table S3 demonstrates a much more even distribution of
biobanks across the various types of practices concerning researchers.
ADDRESSING CHALLENGES
Within the context of rapidly expanding genomic and bioinformatic capacities and the rise
of “next-generation biorepository research” (10), challenges remain in obtaining consent,
protecting participant privacy, and maintaining public trust (20). One response to these
challenges is greater emphasis on the stewardship model of governance. Stew-ardship itself,
rooted in religious ethics, offers a commitment to care for and preserve that which we value
(21). In biobanking, the model provides a powerful ethical framework on which to augment
our current reliance on and specificity of informed-consent protocols to guide decision-
making and preserve public trust (13, 22). The model can also address the ethical quandary
that emerges from the need to balance the rights of specimen contributors with scientists’
quest for broad open access to data derived from human tissue (11).
Several scholars emphasize the importance of establishing governance models when
addressing the various challenges of biobanking, and present models consonant with
stewardship (23). For example, O'Doherty and colleagues offer a conceptual model of
adaptive governance, which holds management accountable for participant interests through
specific governance bodies, existing mechanisms (such as Institutional Review Boards and
scientific oversight committees), and communication channels (13). The “honest broker”
model, currently in use at a number of U.S. institutions, ensures access to clinical specimens
for research while protecting contributor identities (24, 25). Others focus on the protection
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inherent in responsible researcher actions. For example, in an international study of ethical
norms and rules governing biobanking, Capron and colleagues found that investigators and
policy-makers generally regard MTAs as an “effective and appropriate vehicle for ensuring
responsible management of the samples and data entrusted to genetic repositories” (26).
Reflecting the values of nonmaleficence and f delity, respondents interviewed for the
Capron study said that such restrictions “would prevent abuses (material ‘falling into wrong
hands’), would protect participants’ autonomy (against secondary uses not authorized in the
original informed consent document), and would honor participants’ trust in the repository”
(26).
Although recent biobank best practices guidance documents do not specifically discuss
stewardship as a model of governance, they do address standards for trustworthy acquisition,
storage, management, and transfer of specimens and related data (16, 17). In addition, the
College of American Pathologists (CAP) created a Biorepository Accreditation Program
(BAP) in 2012. The BAP and best practices documents provide guidance for technical
procedures, effective organizational features, and practices regarding responsible
relationships with specimen contributors and researchers (18). However, implementing these
various forms of guidance recommendations is voluntary, and there is no required
registration of biobanks that might facilitate adoption of certain standards. Thus, there are
almost no data on the extent to which biobanks are following these recommendations. Our
study provides such empirical data and also articulates various dimensions of steward-ship
to demonstrate how the model might be applied to address ethical tensions that arise in
storage and use across the life span of human specimens for biomedical research. We found
that, among biobanks that are able to engage with contributors because they retain
identifying information, most take a minimalist approach, with very few biobanks creating
such relationships.
If we include practices that span the life of the specimen—that is, how biobanks care for
specimens even when no relationships with contributors persist—our conclusions are quite
different. Biobanks protect the interests of their contributors with the use of internal
practices and in their dealings with researchers, and demonstrate considerable stewardship
of the specimens, albeit with variability on some measures. Our assessment of internal
practices reveals a high level of standardization of processing, tracking procedures, and
oversight of proper research use. Less common are the practices more recently highlighted
in the literature regarding biobank sustainability, such as business or termination plans,
where we find a minority of biobanks reporting that they have taken such steps (19). With
regard to stewardship during and after specimen transfer, our results show that most bio-
banks impose restrictions on researchers. Our matrix analysis of 370 biobanks demonstrates
that 72% impose at least two of the four restrictions measured, and that most biobanks fall
between a minimalist and maximalist approach, with no dominant pattern of researcher
practices.
This exploration of stewardship practices in a national survey of biobanks is not without
limitations. Future surveys should include additional measures of how specimens are cared
for within the biobank. In addition, while we report the type of consent approach used, we
do not know which consent approach offers more protections to contributors and their
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interests, an important topic to be pursued (27–29). Likewise, we report whether biobanks
require researchers to pay for specimens beyond shipping and handling fees, but we do not
know whether these are intended for cost recovery or profit. Lastly, given the great
heterogeneity in biobanks’ organizational features (30), there are a number of contextual
factors related to their mission, governance structure, and funding sources that may limit the
appropriateness or their ability to adopt particular stewardship practices.
In viewing biobank practices, did we glimpse stewardship in action? We think so. However,
what is now needed is a full articulation of the range of best practices for bio-banks that
address the ethics of stewardship and research that examines whether and how a fully
articulated stewardship model can meet the fundamental challenge inherent in biobanking:
ensuring respect for the individuals who contribute specimens while facilitating research
conducted for the public's benefit.
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Fig. 1. Practices for contributors
(A) Questions and skip patterns used to determine whether and how contributors are
informed that their specimens will be stored for future research. (B) Questions and skip
patterns regarding return of results to contributors.
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Fig. 2. Biobank reach-through
Questions and skip patterns regarding disposition of remaining specimens.
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Table 1
Reasons biobank does not approve some requests.
Reason n %
Scientific merit of proposed study 123 57
Lack of specimen availability 92 43
Lack of IRB approval 45 21
Lack of other needed approvals 26 12
Research aims do not address biobank mission 19 9
Funding 17 8
Researcher credentials 15 7
Researcher not affiliated with biobank 13 6
Ethical concerns about proposed research 8 4
Other reason 10 5
Total 216
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Table 2
Basis for giving priority access to some researchers.
Reason n %
Scientific merit of proposed study 124 66
Feasibility of proposed study 105 56
Researcher affiliated with biobank 85 45
Research aims address mission of biobank 83 44
Researcher contributed specimens to biobank 79 42
Track record of principal investigator/team 68 36
Other reason 48 26
Total 187
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